重组人血管内皮抑制素在静脉输液中的稳定性研究

    Stability Study of Endostatin in PVC, Non-PVC Infusion Bags and Drug Infusion Pumps

    • 摘要: 目的 考察重组人血管内皮抑制素注射液(恩度)在静脉输液中的稳定性,为临床合理用药提供依据。方法 模拟临床给药剂量和给药时间,采用高效液相色谱法测定重组人血管内皮抑制素注射液在聚氯乙烯(PVC)输液袋、非PVC输液袋及全自动注药泵中不同温度、不同时间点的药物浓度。结果 在25 ℃或37 ℃下,重组人血管内皮抑制素注射液在PVC和非PVC氯化钠输液中至少保持稳定4 h,在全自动注药泵中48 h内保持稳定。结论 在临床实践中,重组人血管内皮抑制素注射液以PVC和非PVC材质的0.9%氯化钠注射液500 mL静脉点滴2 h或全自动注药泵(250 mL)恒速给药24 h,从药品稳定性角度讲是可行的。

       

      Abstract: OBJECTIVE To investigate the stability of endostatin in PVC infusion bags, non-PVC infusion bags and drug infusion pumps. METHODS In a simulated clinical situation, endostatin was undergone appropriate dilution with 0.9% sodium chloride injection in PVC infusion bags, non-PVC infusion bags or drug infusion pumps. Then high-performance liquid chromatography (HPLC) was employed to determine endostatin concentrations at 0, 1, 2, 4 h or 0, 4, 8, 16, 24 h under 25 ℃ or 37 ℃. RESULTS Endostatin could keep stable in PVC infusion bags or non-PVC infusion bags for at least 4 h, and remained stable for 48 h in drug infusion pumps under 25 ℃ or 37 ℃. CONCLUSION In clinical practice, it is appropriate to administer endostatin by intravenous dripping or via automatic infusion pumps from the perspective of drug stability.

       

    /

    返回文章
    返回